AFT Pharmaceuticals (ASX:AFP) Net Income From Continuing Operations : A$10.2 Mil (TTM As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is AFT Pharmaceuticals Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. AFT Pharmaceuticals's net income from continuing operations for the six months ended in Sep. 2023 was A$1.7 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Sep. 2023 was A$10.2 Mil.

AFT Pharmaceuticals Net Income From Continuing Operations Historical Data

The historical data trend for AFT Pharmaceuticals's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AFT Pharmaceuticals Net Income From Continuing Operations Chart

AFT Pharmaceuticals Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Net Income From Continuing Operations

Get a 7-Day Free Trial

-2.34

12.36

7.20

18.49

9.91

AFT Pharmaceuticals Semi-Annual Data
	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Net Income From Continuing Operations	Get a 7-Day Free Trial											4.09	14.53	1.29	8.56	1.68

AFT Pharmaceuticals Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$10.2 Mil.

AFT Pharmaceuticals (ASX:AFP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AFT Pharmaceuticals Ltd (ASX:AFP) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

AFT:New Zealand

Address

129 Hurstmere Road, Level 1, Takapuna, Auckland, NTL, NZL, 0622

Website

https://www.aftpharm.com

AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Aqueous cream, Calci-tab, Maxigesic, Cromo-fresh, Crystaderm, Crytawash, Ellgy plus, Emulsifying ointment, and others. The group has four operating segments based on geographical location being, Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia which includes the sales and distribution activity relating to the Australian market.

AFT Pharmaceuticals (ASX:AFP) Headlines

No Headlines